STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Meda’s (STO:MEDAA) partner for Retigabine, Valeant Pharmaceuticals, today announced that Retigabine completed both the New Drug Application (NDA) and the Marketing Authorisation Application (MAA) submissions on October 30, 2009.
